DBPR108 [CAS 1186426-66-3]

DBPR108 is a potent, selective, and orally bioavailable dipeptide-derived inhibitor of DPP4 with IC50 of 15 nM; no inhibition on DDP8 and DPP9. IC50 value: 15 nM [1] Target: DPP4 inhibitor DBPR108 is an IC50=15 nM DPP IV inhibitor displays a more than 3000-fold selectivity over DPP8 DPP9, FAP and DPP-II. TThe in vivo effects of DBPR108, including inhibition of plasma DPP-IV activity and suppression of blood glucose elevation, were also demonstrated. DBPR108 is a potent, selective, long-acting and safe DPP-IV inhibitor as a potential treatment of type 2 diabetes mellitus.

[1186426-66-3]

C16H25FN4O2

324.39

N#C[C@H]1N(C(CNC(C)(C)CC(N2CCCC2)=O)=O)C[C@@H](F)C1

Dipeptidyl Peptidase

DPP-4

99.93

DMSO : ≥ 25 mg/mL

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature

H315, H319, H335

H315, H319, H335